NEW AMSTERDAM SCIENCES

New Amsterdam Sciences (NAS) is a clinical-stage bioscience company focused on the research, development and licensing of small molecule antioxidant SOD mimetics and peptide analogues of Substance P. The company’s lead compound, NAS150, is being pursued for indications including Progressive Supranuclear Palsy, Idiopathic Pulmonary Fibrosis, and Radiation-Induced Lung Injury. New Amsterdam Sciences is devoted to developing products with not only commercial value but having governmental appeal, with a focus on mass casualty biodefense applications.